TYROSINE KINASES IN CANCER RECURRENCE
With
Dr Yu Yu
Program Lead, Curtin Medical Research Institute &
Senior Research Fellow, Curtin Medical School,
Curtin University, Perth, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | July 2025
Dr Yu Yu completed her PhD at Faculty of Medicine, University of Sydney in experimental therapeutics for cancer. She then pursued postdoctoral training at the Richard W. TeLinde Gynecologic Pathology Laboratory, Johns Hopkins University School of Medicine, USA with a focus on understanding the treatment for recurrent ovarian tumour.
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu has a strong expertise in developing molecular and cellular therapeutics for cancer. She is a former NHMRC Peter Doherty Fellow and Raine/Robson Fellow. Her studies focused on recurrent cancers, with interests in biomarker and therapeutics development.
Ovarian cancer is one of the deadliest gynaecologic cancers. There are ~300,000 new cases of ovarian cancer worldwide each year. Less than half of women diagnosed survive 5-years after diagnosis. Platinum-based chemotherapy is used to treat ovarian cancers and a variety of other solid cancers. The National Cancer Institute reports 20% of cancer patients worldwide (3.6 million people) receive a platinum-based drug as part of treatment. However, ~20-50% do not respond because of intrinsic resistance. Currently, there is no way to predict response prior to starting platinum chemotherapy.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
Collaboration partners include St John of God Hospital and King Edward Memorial Hospital, both in Western Australia. Funding for Dr Yu Yu’s research comes from WA Department of Health’s Future Health and Innovation Research Fund, Raine Medical Research Foundation and Endometriosis Foundation of America.
Source: Supplied and adapted
https://orcid.org/0000-0002-0209-0586
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Blister management and impact on firefighters
David Burns, a Senior Paramedic with LifeAid, a private paramedicine company in Victoria and, has a diverse background in healthcare. He began his career as a registered nurse, progressing to critical care nursing specialising in liver transplants and cardiovascular surgery.
At the Australasian College of Paramedicine International Conference, David presented research focused on the foot care of firefighters during prolonged bushfire campaigns. During the 2019-2020 bushfires, over 10,000 firefighters sought care, with nearly 50% requiring attention for foot-related issues. David emphasised that inadequate foot care could bench firefighters for up to 10 days, diminishing their ability to protect communities and critical infrastructure. Recognising the economic benefits of prioritising firefighter health, David advocates that ensuring their well-being allows communities to recover effectively and enhances safety for all involved in firefighting efforts.
-
RESEARCH IMPACT SAHMRI, SOUTH AUSTRALIA (2023)
South Australian Health and Medical Research Institute, also known as SAHMRI has had significant impacts in various areas over the past ten years, and this year is celebrating its 10 year anniversary with a week of events.
Ahead of the anniversary, Executive Director, Professor Maria Makrides spoke to Bench Side Story about 3 achievements in the past 10 years that have had significant impact
